Psyched Wellness Ltd.

Recent News

  • Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation

    Toronto, Ontario--(Newsfile Corp. - October 19, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the preliminary data revealing a potential new functional property and health benefit of AME-1.Preliminary data that has been generated in tests done by the National Research Council of Canada (NRC) shows that AME-1 extract can inhibit human connective-tissue...

    2021-10-19 7:30 AM EDT
  • Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

    Toronto, Ontario--(Newsfile Corp. - October 7, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that KGK Science, a licensed contract research organization (CRO) in Canada, is commencing the next pre-clinical trial study on Psyched's key proprietary extract, Amanita Muscaria (AME-1).The trial will comprise a conditioned placement preference study (CPP) in order to establish...

    2021-10-07 7:00 AM EDT
  • Psyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)

    Toronto, Ontario--(Newsfile Corp. - September 22, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce it has been included in the new AdvisorShares Psychedelics Exchange Traded Fund (ETF). Listed on the NYSE Arca under the ticker symbol ('PSIL'), the ETF currently includes 23 psychedelics companies and actively manages investments in the emerging psychedelic drugs...

    2021-09-22 7:30 AM EDT
  • Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1

    Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce it has initiated first steps towards a clinical sleep study for a structure/function claim for the Company's proprietary extract from Amanita Muscaria mushrooms, AME-1.The study will be led by Psyched Wellness's Board member and Head of the Company's Scientific...

    2021-09-21 7:30 AM EDT
  • Psyched Wellness Announces Participation in the H.C. Wainwright 23rd Annual Global Investment Conference

    Toronto, Ontario--(Newsfile Corp. - September 10, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional mushrooms, is pleased to announce that CEO, Jeffrey Stevens and COO, David Shisel will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually on September 13-15, 2021.A recording of Psyched's presentation will be available on-demand from Monday, September 13th at 7:00...

    2021-09-10 7:00 AM EDT
  • Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

    Toronto, Ontario--(Newsfile Corp. - September 8, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional mushrooms, is pleased to announce the Company, in collaboration with KGK, a licensed CRO in Canada, is commencing the next preclinical trial study on Amanita Muscaria Extract (AME-1). The trial will comprise a neurobehavioral study focusing on determining the neurotoxicity effects of AME-1 on functional...

    2021-09-08 7:00 AM EDT
  • Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its Work on the AME-1

    Toronto, Ontario--(Newsfile Corp. - August 17, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company has submitted applications to the United States Patent and Trademark office, for four further provisional patents surrounding the Company's flagship product - AME-1.The applications were submitted on August 11, 2021 as such:App US63/232,144: THERAPEUTIC COMPOSITIONS OF...

    2021-08-17 7:30 AM EDT
  • Psyched Wellness Enters into a Service Agreement with CannaLabs to Begin Stability Tests on AME-1

    Toronto, Ontario--(Newsfile Corp. - July 26, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the Company has entered into a service agreement with CannaLabs, a Canadian, London-based laboratory services company, licensed by Health Canada.According to the agreement, Psyched Wellness will use the services of CannaLabs to perform stability tests on the Company's AME-1....

    2021-07-26 7:30 AM EDT